NEW YORK, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that President and CEO Elma Hawkins, PhD, will participate in the following upcoming investor conferences:
Jefferies Autumn 2015 Global Healthcare Conference
Date: Wednesday – Thursday, November 18-19, 2015
Location: The May Fair Hotel, London
Piper Jaffray 27th Annual Healthcare Conference
Date: Tuesday – Wednesday, December 1-2, 2015
Location: The New York Palace Hotel, New York
Roth Immuno-Oncology Corporate Access Day
Date: Wednesday, December 16, 2015
Location: Park Hyatt, New York
About Lion Biotechnologies
Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) for the treatment of patients with refractory metastatic melanoma, and is based on a clinical Cooperative Research and Development Agreement with the National Cancer Institute. TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and Moffitt Cancer Center. For more information, please visit http://www.lionbio.com.
Forward Looking Statements
This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties described in the Company's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Investor Relations
The Trout Group
Elizabeth Broder
646-378-2945
ebroder@troutgroup.com
Released November 16, 2015